Spruce Biosciences Net Worth
Spruce Biosciences Net Worth Breakdown | SPRB |
Spruce Biosciences Net Worth Analysis
Spruce Biosciences' net worth analysis, or its valuation, is the process of determining the total value of the company. This involves assessing a range of factors, including Spruce Biosciences' financial performance, assets, liabilities, and potential for growth. The ultimate goal is to provide a clear understanding of Spruce Biosciences' overall worth, which can help investors make informed investment decisions. There are several methods that can be used to perform Spruce Biosciences' net worth analysis. One common approach is to calculate Spruce Biosciences' market capitalization.Another approach is to use the price-to-earnings ratio (P/E ratio), which compares Spruce Biosciences' stock price to its earnings per share (EPS). Discounted cash flow (DCF) analysis is another popular method for assessing Spruce Biosciences' net worth. This approach calculates the present value of Spruce Biosciences' future cash flows, taking into account factors such as growth rate, profitability, and risk. By comparing the present value of Spruce Biosciences' cash flows to its current stock price, investors can gain a better understanding of the company's overall value. Finally, investors may use comparable company analysis to evaluate Spruce Biosciences' net worth. This involves comparing Spruce Biosciences' financial metrics to similar companies in the same industry. By identifying companies with similar financial characteristics, investors can gain insight into Spruce Biosciences' net worth relative to its peers.
Enterprise Value |
|
To determine if Spruce Biosciences is a good investment, evaluating the company's potential for future growth is also very important. This may include expanding into new markets, launching new products or services, or improving operational efficiency. Companies with strong growth prospects can be more attractive investments. This aspect of the research should be conducted in the context of the overall market and industry in which the company operates and should include an analysis of growth potential, competitive landscape, and any regulatory or economic factors that could impact the business. Some of the essential points regarding Spruce Biosciences' net worth research are outlined below:
| Spruce Biosciences generated a negative expected return over the last 90 days | |
| Spruce Biosciences has some characteristics of a very speculative penny stock | |
| Spruce Biosciences has high historical volatility and very poor performance | |
| Spruce Biosciences has a very high chance of going through financial distress in the upcoming years | |
| The company reported the previous year's revenue of 10.09 M. Net Loss for the year was (47.92 M) with loss before overhead, payroll, taxes, and interest of (42.33 M). | |
| Spruce Biosciences currently holds about 93.3 M in cash with (33.27 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 3.96, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| Spruce Biosciences has a frail financial position based on the latest SEC disclosures | |
| Latest headline from thelincolnianonline.com: Spruce Biosciences, Inc. Receives 3.90 Consensus Target Price from Brokerages |
Spruce Biosciences uses earnings reports to provide investors with an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Therefore, it is also crucial when considering investing in Spruce Biosciences. Every quarterly earnings report provides investors with an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Spruce Biosciences' previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
| 21st of March 2024 Upcoming Quarterly Report | View | |
| 20th of May 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 21st of March 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
Know Spruce Biosciences' Top Institutional Investors
Have you ever been surprised when a price of an equity instrument such as Spruce Biosciences is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Spruce Biosciences backward and forwards among themselves. Spruce Biosciences' institutional investor refers to the entity that pools money to purchase Spruce Biosciences' securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Lion Point Capital, Lp | 2024-09-30 | 75 K | Northern Trust Corp | 2024-09-30 | 74.9 K | State Street Corp | 2024-09-30 | 64.4 K | Bridgeway Capital Management, Llc | 2024-09-30 | 40 K | Shay Capital Llc | 2024-09-30 | 38.1 K | Two Sigma Advisers, Llc | 2024-09-30 | 27.1 K | Two Sigma Investments Llc | 2024-09-30 | 23.4 K | Xtx Topco Ltd | 2024-09-30 | 19.1 K | Jane Street Group Llc | 2024-09-30 | 15.7 K | Rivervest Venture Management Llc | 2024-09-30 | 2.9 M | The Carlyle Group Inc | 2024-09-30 | 2.9 M |
Follow Spruce Biosciences' market capitalization trends
The company currently falls under 'Micro-Cap' category with a current market capitalization of 15.07 M.Market Cap |
|
Project Spruce Biosciences' profitablity
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (0.41) | (0.44) | |
| Return On Capital Employed | (0.59) | (0.62) | |
| Return On Assets | (0.41) | (0.44) | |
| Return On Equity | (0.72) | (0.68) |
When accessing Spruce Biosciences' net worth, it's important to look at multiple sources and consider different scenarios. For example, gross profit margin measures Spruce Biosciences' profitability after accounting for the cost of goods sold, while net profit margin measures profitability after accounting for all expenses. Other important metrics include return on assets, return on equity, and free cash flow. By reviewing multiple sources and metrics, you can gain a complete picture of Spruce Biosciences' profitability and make more informed investment decisions.
Please note, the presentation of Spruce Biosciences' financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Spruce Biosciences' management is honest, while the outside auditors are strict and uncompromising. Please utilize our Beneish M Score to check the likelihood of Spruce Biosciences' management manipulating its earnings.
Evaluate Spruce Biosciences' management efficiency
Spruce Biosciences has return on total asset (ROA) of (0.3035) % which means that it has lost $0.3035 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.5755) %, meaning that it created substantial loss on money invested by shareholders. Spruce Biosciences' management efficiency ratios could be used to measure how well Spruce Biosciences manages its routine affairs as well as how well it operates its assets and liabilities. As of January 21, 2025, Return On Tangible Assets is expected to decline to -0.44. In addition to that, Return On Capital Employed is expected to decline to -0.62. The current year's Other Current Assets is expected to grow to about 7.1 M, whereas Total Assets are forecasted to decline to about 89.5 M.| Last Reported | Projected for Next Year | ||
| Book Value Per Share | 1.79 | 1.48 | |
| Tangible Book Value Per Share | 1.79 | 1.48 | |
| Enterprise Value Over EBITDA | (0.40) | (0.42) | |
| Price Book Value Ratio | 1.33 | 1.39 | |
| Enterprise Value Multiple | (0.40) | (0.42) | |
| Price Fair Value | 1.33 | 1.39 | |
| Enterprise Value | 24.3 M | 23.1 M |
The strategic initiatives led by Spruce Biosciences' management are central to its market success. By analyzing these initiatives, we provide a clear picture of the stock's growth prospects.
Enterprise Value Revenue 15.3227 | Revenue | Quarterly Revenue Growth (0.80) | Revenue Per Share | Return On Equity |
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Spruce Biosciences insiders, such as employees or executives, is commonly permitted as long as it does not rely on Spruce Biosciences' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Spruce Biosciences insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Spruce Biosciences time-series forecasting models is one of many Spruce Biosciences' stock analysis techniques aimed to predict future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary Spruce Biosciences' historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.
Spruce Biosciences Earnings per Share Projection vs Actual
Spruce Biosciences Corporate Management
| CPA CPA | Pres CFO | Profile | |
| MD III | Chief Officer | Profile | |
| Libbie MBA | Chief Officer | Profile | |
| P Ramtin | Senior Operations | Profile | |
| Heidi MPH | Senior Quality | Profile |
Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Spruce Biosciences. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area. For information on how to trade Spruce Stock refer to our How to Trade Spruce Stock guide.You can also try the Cryptocurrency Center module to build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Spruce Biosciences. If investors know Spruce will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Spruce Biosciences listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.95) | Revenue Per Share | Quarterly Revenue Growth (0.80) | Return On Assets | Return On Equity |
The market value of Spruce Biosciences is measured differently than its book value, which is the value of Spruce that is recorded on the company's balance sheet. Investors also form their own opinion of Spruce Biosciences' value that differs from its market value or its book value, called intrinsic value, which is Spruce Biosciences' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Spruce Biosciences' market value can be influenced by many factors that don't directly affect Spruce Biosciences' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Spruce Biosciences' value and its price as these two are different measures arrived at by different means. Investors typically determine if Spruce Biosciences is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Spruce Biosciences' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.